 NEW YORK, NY ACCESSWIRE March 25, 2021 Kadmon Holdings, Inc. NASDAQ:KDMN today announced it will present a trial-in-progress poster on KD033-101, the Companys ongoing dose-escalation, dose-expansion trial of KD033 in patients with metastatic and locally advanced solid tumors, at the 2021 American Association for Cancer Research AACR Annual Meeting, taking place virtually April 10 - 15, 2021. KD033 is currently being evaluated in an ongoing Phase 1 study in patients with metastatic or locally advanced solid tumors. 